New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 13, 2012
10:25 EDTPRGO, CPIXCumberland enters settlement with Paddock, Perrigo for Acetadote patent
Cumberland (CPIX) disclosed this morning that it entered into a settlement agreement with Paddock and Perrigo to resolve the challenges and the pending litigation between the company and each of Paddock and Perrigo (PRGO) involving its Acetadote patent. Under the agreement, Paddock and Perrigo admit that the Acetadote patent is valid and enforceable and that any Paddock or Perrigo generic Acetadote would infringe upon the Acetadote patent. In addition Paddock and Perrigo will not challenge the validity, enforceability, ownership or patentability of the Acetadote patent through its expiration currently scheduled for May 2026. The agreement provides, among other things, that within three days of execution, the parties will file with the respective Illinois and Delaware courts all necessary papers required to dismiss without prejudice all claims and counterclaims, motions and petitions asserted in the above referenced lawsuits In connection with the execution of the settlement agreement, Cumberland entered into a License and Supply Agreement with Paddock and Perrigo. Under the terms, if a third party receives final approval from the FDA to sell a generic Acetadote product, Cumberland will supply Perrigo with an authorized generic version of the Acetadote product. Perrigo agrees to sell the authorized generic and that it would share with Cumberland the net sales revenues.
News For CPIX;PRGO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 24, 2014
07:57 EDTPRGOPerrigo confirms first to file patent challenge for generic version of Aveed
Subscribe for More Information
07:53 EDTPRGOPerrigo announces launch of generic version of Astellas' Protopic ointment
Perrigo announced that it has agreed to market the authorized generic version of Astellas U.S. LLC's' Protopic Ointment 0.1% and 0.03%. Shipments to our pharmacy customers have commenced. Protopic Ointment is indicated to treat moderate to severe eczema. Brand sales were approximately $176M over the last 52 weeks according to Symphony Health Solutions.
November 21, 2014
14:17 EDTPRGOPerrigo price target raised to $184 from $175 at CRT Capital
Subscribe for More Information
10:20 EDTPRGOHigh option volume stocks
Subscribe for More Information
November 20, 2014
20:07 EDTPRGOPerrigo 5.92M share Secondary priced at $152.00
Subscribe for More Information
10:33 EDTPRGOHigh option volume stocks
High option volume stocks: KBR LM PRGO CHRW DG ZMH LGF ZTS OSIR REGI
06:56 EDTPRGOPerrigo files to sell $900M in ordinary shares
Perrigo intends to use the net proceeds of the offering, together with the proceeds of other financing sources, to fund the cash consideration for its proposed acquisition of Omega Pharma Invest NV and to repay or refinance certain indebtedness of Perrigo and/or Omega. If the Acquisition is not consummated, then the net proceeds of the offering will be used for general corporate purposes. J.P. Morgan, Barclays and BofA Merrill Lynch are the joint book-running managers in the offering.
06:56 EDTPRGOPerrigo files automatic mixed securities shelf
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use